HC Wainwright & Co. Reiterates Buy on Genmab, Maintains $49 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Genmab (NASDAQ:GMAB) and maintained a $49 price target for the company's stock.
November 20, 2023 | 4:42 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates a Buy rating on Genmab and maintains a $49 price target.
The reiteration of a Buy rating and maintenance of a price target by a reputable analyst can instill confidence in investors and positively influence the stock price in the short term. The specific mention of Genmab and the reaffirmation of the price target suggest a strong conviction in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100